Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase 1 Study of E7389 Liposomal Formulation in Subjects With Solid Tumor

Next Previous
X
Search
Trial Profile

An Open-label Phase 1 Study of E7389 Liposomal Formulation in Subjects With Solid Tumor

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary)
  • Indications Adenocarcinoma; Adenoid cystic carcinoma; Advanced breast cancer; Gastric cancer; HER2 negative breast cancer; Oesophageal cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions
  • Sponsors Eisai Co Ltd

    • Most Recent Events

    • 29 Feb 2024 Planned End Date changed from 31 Aug 2024 to 31 Aug 2025.
    • 24 Oct 2023 Results (n=26; At the data cutoff date October 26, 2022) assessing the efficacy and safety data from the dose-expansion part in patients with metastatic/advanced HER2-negative breast cancer, presented at the 48th European Society for Medical Oncology Congress.
    • 11 Oct 2023 According to an Eisai Co Ltd media release, the company will present findings from the dose-expansion portion in patients with metastatic/advanced HER2-negative breast cancer during the European Society for Medical Oncology (ESMO) Congress 2023, which is taking place virtually and in-person in Madrid, Spain from October 20 to 24.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top